LPIN1 downregulation enhances anticancer activity of the novel HDAC/PI3K dual inhibitor FK-A11.

Imai, Hiroo; Saijo, Ken; Chikamatsu, Sonoko; Kawamura, Yoshifumi; Ishioka, Chikashi

Imai, Hiroo; Saijo, Ken; Chikamatsu, Sonoko; Kawamura, Yoshifumi; Ishioka, Chikashi.

Afiliação

Imai H; Department of Clinical Oncology, Institute for Development, Aging and Cancer, Tohoku University, Sendai, Japan.
Saijo K; Department of Clinical Oncology, Institute for Development, Aging and Cancer, Tohoku University, Sendai, Japan.
Chikamatsu S; Department of Clinical Oncology, Institute for Development, Aging and Cancer, Tohoku University, Sendai, Japan.
Kawamura Y; Department of Clinical Oncology, Institute for Development, Aging and Cancer, Tohoku University, Sendai, Japan.
Ishioka C; Department of Clinical Oncology, Institute for Development, Aging and Cancer, Tohoku University, Sendai, Japan.

Cancer Sci ; 112(2): 792-802, 2021 Feb.

Article em En | MEDLINE | ID: mdl-33274548

Assuntos

Antineoplásicos/farmacologia; Inibidores de Histona Desacetilases/farmacologia; Fosfatidato Fosfatase/metabolismo; Inibidores de Fosfoinositídeo-3 Quinase/farmacologia; Animais; Linhagem Celular Tumoral; Proliferação de Células/efeitos dos fármacos; Regulação para Baixo; Feminino; Humanos; Camundongos; Camundongos Endogâmicos BALB C; Camundongos Nus; Ensaios Antitumorais Modelo de Xenoenxerto

Palavras-chave

LPIN1; dual HDAC/PI3K inhibitor; histone deacetylase; phosphatidylinositol-3 kinase; propranolol

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fosfatidato Fosfatase / Inibidores de Histona Desacetilases / Inibidores de Fosfoinositídeo-3 Quinase / Antineoplásicos Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google